Reduction of Adverse Drug Events and Readmissions

Recruiting

• Conditions: Pharmacogenomic Testing for Medication Management

• Registration Number: NCT02738047
• Lead Sponsor: ClinLogic LLC

Brief Summary

Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.

Detailed Description

Pharmocogenomic. A multicenter, observational study to evaluate the use of a Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known to be influenced by genetic variation.

Study Timeline

• Study First Submitted: 2016-03-28
• Study First Submitted QC: 2016-04-08
• Study First Posted: 2016-04-14
• Study Start: 2019-03-15
• Status Verified: 2023-12
• Last Update Submitted: 2024-02-06
• Last Update Posted: 2024-02-07
• Primary Completion: 2025-03
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 280000

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Radar, Pharmocogenomic	The period of enrollment is anticipated to be 36 months with a 120- day follow-up period, for total study duration of approximately 40 months from first patient enrolled to completion of follow-up on the last patient in.	The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each patient when: 1. A genotype known to affect a drug the patient is taking is identified, \*and\*; 2. The patient's treating physician makes at least one target drug regimen change, dose, substitution, or discontinuation.; Change in drug dose, substitution, or discontinuation among patients with an identified genotype known to affect a drug the patient is taking as directed. This will be assessed by a quantitative survey.

Trial Locations

Locations (1)

MD@Home; 🇺🇸 York, Pennsylvania, United States